Los Angeles Capital Management LLC Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Los Angeles Capital Management LLC grew its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 158.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 114,535 shares of the biopharmaceutical company’s stock after purchasing an additional 70,238 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.07% of ACADIA Pharmaceuticals worth $2,102,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in ACAD. State Street Corp boosted its position in shares of ACADIA Pharmaceuticals by 3.0% in the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock worth $91,878,000 after acquiring an additional 173,084 shares during the last quarter. Fred Alger Management LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 17.8% in the 3rd quarter. Fred Alger Management LLC now owns 3,186,389 shares of the biopharmaceutical company’s stock valued at $49,007,000 after purchasing an additional 481,950 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company’s stock valued at $44,234,000 after purchasing an additional 30,826 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after buying an additional 1,966,607 shares during the period. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of ACADIA Pharmaceuticals by 19.5% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 1,139,934 shares of the biopharmaceutical company’s stock worth $17,532,000 after buying an additional 185,684 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ ACAD opened at $19.60 on Friday. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $14.15 and a fifty-two week high of $24.53. The business has a 50 day moving average price of $18.37 and a two-hundred day moving average price of $16.81. The firm has a market cap of $3.26 billion, a PE ratio of 25.13 and a beta of 0.37.

Analyst Ratings Changes

A number of brokerages recently weighed in on ACAD. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday. Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. Finally, StockNews.com lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $24.00.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.